The European Commission has asked the SCCS to assess the safety of Hydroxyapatite (nano). On 15-16 March 2022, the SCCS accepted this mandate and the Committee has six months to deliver its Opinion.
This content is only available to Premium Members.
Get access to all our Premium content and services.
Start your Free Trial or Discover our plans.
Already a Premium member? Sign In
Cannabidiol (CBD) is one of the approximately hundred naturally occurring cannabinoids found in Cannabis plants and may account for up to 40 % of the plant’s extract. However, there is no definition of CBD in Read more…
The Commission requests an addendum to SCCS/1658/23 to cover children’s exposure to HexylSalicylate (hexyl 2-hydroxybenzoate; CAS/EC No. 6259-76-3/228-408-6) from cosmetic products.
The Commission requests the SCCS to carry out a safety assessment on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466- 77-3/83834-59-7, EC No. 226-775-7/629-661-9). The Committee has nine months to deliver its Opinion.